We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
1452 GMT - Roche Holding AG is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after the company's 2022 profit missed expectations and guided for lower sales and earnings in 2023 due to declining Covid-19 sales. The Swiss pharma major's 2022 sales rose on-year and were in line with consensus, though its net profit dropped and missed expectations. It confirmed a CHF5 billion hit from missed Covid-19 product sales as previously announced. For the year ahead, it said it expects a drop in sales in the low-single digits at constant exchange rates, with earnings per share set to develop in line with the sales decline. Excluding Covid-19 sales decline, Roche expects underlying sales growth in both its divisions. It said it would also further increase its dividend. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
February 02, 2023 10:08 ET (15:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
